久久久国产一区二区_欧美在线小视频_高清一区二区三区_久久综合久久久_成人久久久久久久久_亚洲精品视

上海非利加實業有限公司Logo

熱門詞: 進口電動溫度調節閥結構圖|進口電動溫度調節閥數據表進口電動高溫調節閥-德國進口電動高溫法蘭調節閥進口電動蒸汽調節閥-德國進口電動蒸汽調節閥

當前位置: 首頁 > 所有品牌 > Psivida
Psivida
Psivida Psivida

美國Psivida  
pSivida是一個發展中的小型化,注射,藥物輸送系統的領導。我們開發產品,以治療嚴重或危及生命的疾病,單獨或與其他公司合作。我們已經開發出的設備是如此之小,他們是FDA批準進入眼內的管理,一旦管理他們釋放其藥物的幾個月甚至幾年。

pSivida is a leader in the development of miniaturized, injectable, drug delivery systems. We develop products to treat serious or life threatening diseases alone or in partnership with other companies. We have developed devices that are so small they are FDA approved to be administered into the eye and once administered they release their drug for months and years.
pSivida's lead development product, ILUVIEN?, delivers fluocinolone acetonide (FA). It is designed to be injected into the eye to provide sustained release into the back of the eye for up to three years after a single injection. ILUVIEN has completed two three-year Phase III clinical trials in Diabetic Macular Edema, one of the leading causes of blindness in the developed world. The NDA was submitted to the FDA in May 2011 by our licensee Alimera Sciences and the review is expected to be completed by the end of 2011. ILUVIEN is also in Phase II clinical trials in dry age-related macular degeneration, wet age-related macular degeneration and retinal vein occlusion. These studies are being conducted by Alimera Sciences.
pSivida's two FDA approved sustained release products to treat chronic back of the eye diseases are Retisert? for the treatment of posterior uveitis and Vitrasert? for the treatment of AIDS-related cytomegalovirus (CMV) retinitis. pSivida has licensed both of these products and the technologies underlying them to Bausch & Lomb Incorporated. Vitrasert and Retisert provide sustained release for six to nine months and two and a half years, respectively.
pSivida has a world wide collaborative Research and Development agreement with Pfizer Inc. to develop a long term sustained release implant to deliver latanoprost for patients with ocular hypertension and glaucoma. This collaboration is focused on developing a bioerodible version of pSivida's proprietary Durasert? technology designed to be injected into the subconjunctival space of the eye.
pSivida is developing a series of additional miniaturized, bioerodible sustained release technologies to deliver a range of proteins and small drug molecules to virtually any site in the body. One of these technologies is Tethadur?, a nanostructured bioerodible material.
pSivida's intellectual property portfolio consists of 180 patents either issued or granted for acceptance, over 150 pending applications and 60 patent families.

關于我們客戶服務產品分類法律聲明
主站蜘蛛池模板: 91原创国产 | 国产成人久久蜜一区二区 | 韩国女主播vip | 在线视频区 | 一边摸一边叫床一边爽视频 | 日韩视频观看 | 国产精品麻豆a在线播放 | 国产欧美日韩综合二区三区 | 欧美色图第一页 | 亚洲欧美日韩另类在线专区 | 玖玖国产精品 | 久国产精品视频 | 精品一区二区三区免费毛片爱 | 国产高清在线看 | 欧美在线观看一区二区三区 | 日韩一区二区免费视频 | 国产精品欧美一区二区三区不卡 | 日韩精品欧美高清区 | 亚洲视频免费在线观看 | 在线播放国产精品 | 国产高清视频免费在线观看 | 国产日韩欧美视频 | 国产精品免费观看网站 | 欧美激情视频一区 | 亚洲第一导航 | 国产高清在线免费 | 国产日韩欧美在线 | 亚洲一区自拍 | 亚洲欧美中文字幕 | 中文字幕美日韩在线高清 | 欧美日韩在线一区 | 影音先锋亚洲综合小说在线 | 欧美日韩国产另类一区二区三区 | 欧美高清一区二区三区欧美 | 国产成人99久久亚洲综合精品 | 国产精品va一区二区三区 | 亚洲欧美国产精品专区久久 | 日韩在线视频免费 | 日本免费一级视频 | 欧美极品第一页 | 欧美日本综合 |